
ACUTE **PROMYELOCYTIC** LEUKEMIA A CURABLE DISEASE?

November, 11-12 1993

Jolly Hotel Vittorio Veneto Corso d'Italia 1 Roma



ABSTRACT BOOK



ACUTE
PROMYELOCYTIC
LEUKEMIA
A CURABLE DISEASE?
Roma, November 12 – 14, 1997

ROMA - Jolly Hotel Vittorio Veneto - Corso d'Italia 1




4th International Symposium on Acute Promyelocytic Leukemia

Roma, Grand Hotel Parco dei Principi September 29*- October 1*, 2005



CHAIRMEN: F. LO COCO, P.G. PELICCI HONORARY PRESIDENT: F. MANDELLI CO-ORGANIZERS: G. AVVISATI (ITALY), A.K. BURNETT (UK), L. DEGOS (FRANCE), T. NAOE (JAPAN), C. NERVI (ITALY), M.A. SANZ (SPAIN), M.S. TALLMAN (USA), Z. CHEN (CHINA)



With the partnership of

5th INTERNATIONAL SYMPOSIUM ON ACUTE PROMYELOCYTIC LEUKEMIA

Rome, Maintenance Congress Centre Grand Hotel Parco dei Principi, September 24-26, 2009




Chairmen: F. Lo Coco, M.A. Sanz

Honorary President: F. Mandelli

Acute Promyelocytic Leukemia:

From Highly Fatal to Highly Curable





APL: Some open issues

- Early death
- Biology and prognostic factors of coagulopathy
- Mechanisms of ATO and ATRA action/resistance
- Quality of life and long-term sequelae of therapy
- Access to early diagnosis
- Drug availability (at reasonable cost!)

Aims of the Symposium (I)


- Education on diagnosis, management and response evaluation
- Update on advances in biology and treatment
- Provide a forum to young investigators to present their data

Aims of the Symposium (II)


- Discuss strategies to improve patient outcome in less privileged countries
- Discuss drug availability, early death and access to optimal care
- Implement international collaboration

Some international collaborative studies in APL

- Hopital St.Louis (Paris) Shanghai Inst. of Hematology
- International Consortium (IC-APL)
- International Consortium for Children (ICC-APL)
- French-European Group
- US-Canada Intergroup
- Australasian Intergroup
- GIMEMA-PETHEMA (Sanz score)
- PETHEMA-HOVON intergroup
- GIMEMA-AMLSG-SAL (APL0406)
- Hopital St. Louis, Paris CMC Vellore, India
- Peking Univ. Hospital, Tor Vergata Univ. Rome











Session VIII - Management of APL in developing countries I (Monday, 3.10pm)

RIF (oral arsenic) for non-high-risk APL





- 15 days in hospital
- 8 months treatment
- 4,675\$ medical cost

Zhu HH, et al. NEJM 2014 (update on Tuesday, 4.30 pm)

Matched-pair analysis of pts receiving oral vs i.v. arsenic Observation endpoints

EFS

OS

QoL

Costs

Molecular Remission

1° Workshop on RT-PCR of PML/RARA, Rome 1993



David Grimwade Award 2017

Best abstract on translational research in Acute Promyelocytic Leukemia

Presented on Monday, Sept. 25th, 11.30 am




7th INTERNATIONAL SYMPOSIUM ON ACUTE PROMYELOCYTIC LEUKEMIA

Rome, September 24 - 27, 2017


Next Generation APL Leaders Symposium (tomy's Award)

 Educational award program for young hematologists

Monday, Sept 25th, 4.20-5.50 pm



APL International Foundation




Purpose of the Foundation

- The advancement of health and the saving of lives by operating exclusively for health, educational and charitable purposes
- The Foundation has the sole purpose of a non-profit organisation, according to the Charities and Trustee Investment (Scotland) Act 2005 and the Charities Act 2006.

Objectives of the Foundation

- The Foundation will support the fostering of science and research in APL as well as improving and enhancing the medical care of APL patients.
- The Foundation shall promote (but not promote exclusively) its activities and delivery operations internationally to hematologists, clinical nurse specialists, pharmacists, other HCPs, APL patients, their family, friends and carers, and APL patient advocacy groups.
- These people will be the Foundation's beneficiaries and will be provided initially with a trusted online APL resource.



Faculty

Oussama Abla (USA) Lionel Adès (France) Myriam Alcalay (Italy) Sergio Amadori (Italy) William Arcese (Italy) Giuseppe Avvisati (Italy) Nancy Berliner (USA) Massimo Breccia (Italy) Mammen Chandy (India) Zhu Chen (China) Laura Cicconi (Italy) Hughes de Thé (France) Laurent Degos (France) Fabio Efficace (Italy) Elihu Estev (USA) Anna Falanga (Italy) Brunangelo Falini (Italy) Pierre Fenaux (France)

Felicetto Ferrara (Italy) Francesco Grignani (Italy) Syed Khizer Hasan (India) Harry lland (Australia) Anand Jillella (USA) Richard Larson (USA) Soren Lehmann (Sweden) Eva Lengfelder (Germany) Giuseppe Leone (Italy) Junmin Li (China) Francesco Lo Coco (Italy) Franco Locatelli (Italy) Bob Lowenberg ((NL) David Martinez-Cuadron (Spain) Vikram Mathews (India) Wilson H. Miller (Canad) Saverio Minucci (Italy) Pau Montesinos (Spain)

Clara Nervi (Italy) Fabrizio Pane (Italy) Pier Giuseppe Pelicci (Italy) Uwe Platzbecker (Germany) Eduardo Rego (Brazil) Nigel Russell (UK) Guillermo Sanz (Spain) Miguel A. Sanz (Spain) Jaime Sanz Caballer (Spain) Matthew Seftel (Canada) Jorge Sierra (Spain) Akihiro Takeshita (Japan) Martin S. Tallman (USA) Anna Maria Testi (Italy) Christian Thiede (Germany) Adriano Venditti (Italy) Maria Teresa Voso (Italy) Kankan Wang (China)

Participants



- Argentina
- *** Australia
- Austria
- Belgium
- Brasil
- **I** Canada
- China
- **Chile**
- Cyprus
- Czech Republic
- Croatia
- Denmark
- France
- Germany
- Greece
- Hungary







Italy

Japan

Lebanon

Netherlands

Norway

Poland

Portugal

Saudi Arabia

Slovakia

Spain

Suisse

Sweden

UK

USA

Scientific Secretariat



Laura Cicconi



Claudia Carissimo



Maria Teresa Voso



Mariadomenica Divona



Serena Lavorgna



Massimo Breccia

Organizing Secretariat

Barbara Businarolo Cristina Fiorini Elio Baratti Roberta Pasquaroli

Elisabetta Tura

